Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial.

Øvrehus, Anne L H; Krarup, Henrik; Birkemose, Inge; Holm, Dorte K; Mössner, Belinda; Ernst, Anja; Christensen, Peer B

Øvrehus, Anne L H; Krarup, Henrik; Birkemose, Inge; Holm, Dorte K; Mössner, Belinda; Ernst, Anja; Christensen, Peer B.

Affiliation

Øvrehus ALH; Department of Infectious Diseases, Odense University Hospital, Denmark. Electronic address: Anne.Oevrehus@rsyd.dk.
Krarup H; Section of Molecular Diagnostics and Clinical Biochemistry, Aalborg University Hospital, Denmark.
Birkemose I; Odense Drug Treatment Center, Odense Municipality, Denmark.
Holm DK; Department of Clinical Immunology, Odense University Hospital, Denmark.
Mössner B; Department of Infectious Diseases, Odense University Hospital, Denmark.
Ernst A; Section of Molecular Diagnostics and Clinical Biochemistry, Aalborg University Hospital, Denmark.
Christensen PB; Department of Infectious Diseases, Odense University Hospital, Denmark.

J Hepatol ; 68(4): 840-842, 2018 04.

Article in En | MEDLINE | ID: mdl-29223370

Subject(s)
Key words

Direct acting antivirals; Hepatitis C; Intra venous drug use; Randomized clinical trial; Treatment

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Ribavirin / Uridine Monophosphate / Benzimidazoles / Hepatitis C, Chronic / Fluorenes Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: J Hepatol Journal subject: GASTROENTEROLOGIA Year: 2018 Document type: Article Country of publication: Países Bajos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google